News

Shares of Novocure (NASDAQ: NVCR) jumped 18.3% this week, according to data from S&P Global Market Intelligence, after the company announced encouraging results from a phase 3 study of its Tumor

Viking Therapeutics (NASDAQ: VKTX) has emerged this year as a formidable contender in the increasingly popular anti-obesity market. While it doesn't have an approved drug fighting for market share

Relatively small biotechs can see their shares soar -- sometimes significantly -- following positive clinical or regulatory news.

That's what has happened this year to Viking Therapeutics (NASDAQ:

Investors are very eager to buy into biotechs and pharmaceuticals that are involved in developing weight-loss medications. This is why Viking Therapeutics (NASDAQ: VKTX), which has such a drug in

Shares of Novocure (NASDAQ: NVCR) were jumping 6.3% higher as of 11:15 a.m. ET on Thursday after rising as much as 9.2% earlier in the day. The nice gain came after the company announced results

Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because

What's the hottest biotech stock on the market right now? If we limit the list only to those with market caps of at least $500 million, it's Viking Therapeutics (NASDAQ: VKTX). So far in 2024

Shares of Medical Properties Trust (NYSE: MPW) soared 18.6% on Wednesday after the largest tenant of the healthcare facilities-focused real estate investment trust (REIT) announced a deal to sell

Shares of Viking Therapeutics (NASDAQ: VKTX) had skyrocketed by 25% as of 11:08 a.m. ET on Tuesday. That big gain came after the company announced results from a phase 1 clinical study evaluating an

When it comes to rising stars in biotech, Viking Therapeutics (NASDAQ: VKTX) should probably be one of the first businesses to come to mind today. The company doesn't yet have any sales revenue, but

Some investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus Pharmaceuticals several years ago. They'll probably also recall that the initial euphoria over those

Few things are more satisfying than watching a steadily growing stream of passive income flow into your brokerage account. If you've been holding back from investing because you think you can't

Cathie Wood and high dividend yields go together like... well, it's hard to finish that sentence because they don't go together at all. Wood and her Ark Invest funds are known for investing in

There's no shortage of hype and excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock these days. The company has a promising weight loss drug candidate in its pipeline at a time when many

Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks.

Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics

Viking Therapeutics (NASDAQ: VKTX) now ranks among the hottest biotech stocks on the market. The company's announcement in February of positive results from its phase 2 study of experimental weight

Does a rising tide really lift all boats? We could soon find out if the adage applies to the stock market.

A bull market is now well underway. The S&P 500 has soared more than 30% over the last 12

Investors looking for stocks that can deliver heaps of passive income might want to turn their heads toward the healthcare sector. Right now, there are a couple of beaten-down stocks offering

Some investors look at Pfizer (NYSE: PFE) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise have tanked. So have Pfizer's overall revenue

Eli Lilly (NYSE: LLY) has become a giant in what may be a $100 billion market a few years from now. I'm talking about the world of weight loss drugs.

Doctors have been prescribing Mounjaro and the

Dividend-paying stocks have generally outperformed those that don't pay dividends over the long term. That's partly because maintaining a healthy dividend requires a solid underlying business. And

A legal opinion on the other side of Planet Earth put some juice into Illumina's (NASDAQ: ILMN) stock on Thursday. The gene-sequencing specialist saw its share price rise by over 3%, against the S&P

There are potential share price gains, and then there are potential share price gains. In the view of one analyst, Viking Therapeutics (NASDAQ: VKTX) currently stands in front of the latter variety.

If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As